Charles Duncan Analyst Performance

Managing Director & Senior Research Analyst at Cantor Fitzgerald

Charles Duncan is a stock analyst at Cantor Fitzgerald focused in the medical sector, covering 30 publicly traded companies. Over the past year, Charles Duncan has issued 1 stock ratings, including and buy recommendations. While full access to Charles Duncan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Charles Duncan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 196 Last 11 Years
Buy Recommendations: 89.64% 173 Buy Ratings
Companies Covered: 30 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	89.6%	173 ratings
Hold	9.8%	19 ratings
Sell	0.5%	1 ratings

Out of 193 total stock ratings issued by Charles Duncan at Cantor Fitzgerald, the majority (89.6%) have been Buy recommendations, followed by 9.8% Hold and 0.5% Sell.

Best & Worst Calls

Best Call
000000.0%
AXSM
Dec 2018
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
ARGSQ
Jun 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	90.0% of companies on NASDAQ	27 companies
TSE	3.3% of companies on TSE	1 company
NYSE	3.3% of companies on NYSE	1 company
OTCMKTS	3.3% of companies on OTCMKTS	1 company

Charles Duncan, an analyst at Cantor Fitzgerald, currently covers 30 companies listed on NASDAQ, TSE, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 29 companies	96.7%
	Aerospace 1 company	3.3%

Charles Duncan of Cantor Fitzgerald specializes in stock coverage within the Medical sector, with additional focus on Aerospace companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 18 companies	60.0%
MED - DRUGS 5 companies	16.7%
PHARMACEUTICAL PREPARATIONS 4 companies	13.3%
MEDICAL SERVICES 1 company	3.3%
DRUG MANUFACTURERS - SPECIALTY & GENERIC 1 company	3.3%
AEROSP/DEF EQ 1 company	3.3%

About Charles Duncan

Charles has >25 years of sell-side experience, and is a Managing Director and senior biotechnology research analyst at Cantor Fitzgerald. From late 2012 and until early July 2018 he was a Managing Director and senior biotech analyst at Piper Jaffray & Co. Previously he was a founding partner of JMP Securities healthcare group and served as an analyst with that firm since 2002. He has also been a publishing analyst at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. Additionally Charles has achieved Tip Ranks ranking that places him in the top 5% of all analysts and above the majority of other senior biotech analysts.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
SLDB Solid Biosciences	7/21/2025	Set Price Target	$6.73	$16.00	Overweight
CMPS Compass Pathways	3/28/2025	Reiterated Rating	$3.03		Overweight
ACAD ACADIA Pharmaceuticals	2/27/2025	Reiterated Rating	$20.24	$28.00	Overweight
JAZZ Jazz Pharmaceuticals	2/26/2025	Downgrade	$144.60	$150.00	Neutral
AXSM Axsome Therapeutics	2/19/2025	Reiterated Rating	$127.42	$153.00	Overweight
GHRS GH Research	2/13/2025	Initiated Coverage	$14.00	$14.00	Overweight

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.